✦ LIBER ✦

The potential for antitumor vaccination in acute myelogenous leukemia

✍ Scribed by Robert J. Arceci

Book ID: 105797371
Publisher: Springer
Year: 1998
Tongue: English
Weight: 510 KB
Volume: 76
Category: Article
ISSN: 0946-2716
DOI: 10.1007/s001090050195

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The EORTC trials for acute myelogenous l

The EORTC trials for acute myelogenous leukemia

✍ R. Zittoun; for the EORTC Leukemia Cooperative Group 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 157 KB

Evidence for a common leukemia-associate

Evidence for a common leukemia-associated antigen in acute myelogenous leukemia

✍ Abdul Kh. Al-Rammahy; S. Shipman; A. Jackson; A. Malcolm; J. G. Levy 📂 Article 📅 1980 🏛 Springer-Verlag 🌐 English ⚖ 464 KB

Simplified method for the discrimination

Simplified method for the discrimination of acute myelogenous and non-myelogenous leukemias

✍ Hirsch, F. W. ;Engelhardt, R. ;Löhr, G. W. 📂 Article 📅 1983 🏛 Springer-Verlag ⚖ 111 KB

An in vitro model for acute myelogenous

An in vitro model for acute myelogenous leukemia chemotherapy

✍ H. Phillip Koeffler; James Yen; Leslie Lowe 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 611 KB

Antibody therapy for residual disease in

Antibody therapy for residual disease in acute myelogenous leukemia

✍ Joseph G. Jurcic 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 163 KB

The elimination of minimal residual disease remains one of the most promising applications of monoclonal antibody (mAb)-based therapies. An early study showed that treatment with iodine-131 (131I)-labeled anti-CD33 mAb M195 had antileukemic effects when given as postremission therapy to patients wit

Uncertainties in the standard care of ac

Uncertainties in the standard care of acute myelogenous leukemia

✍ Rowe, JM 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 66 KB